New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For HITK;AEZS;AMED;IMGN;HTWR;CRVL;SQNM;MDAS;DSCI;CCRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
15:50 EDTDSCIJames Flynn reports 5.32% passive stake in Derma Sciences
Subscribe for More Information
09:52 EDTHTWRThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTHTWRBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
07:37 EDTAEZSAeterna Zentaris files additional patent application for zoptarelin doxorubicin
Subscribe for More Information
05:32 EDTHTWRHeartWare achieves primary endpoint in ENDURANCE clinical trial
Subscribe for More Information
April 15, 2015
07:41 EDTAEZSEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
10:01 EDTAEZSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:08 EDTAEZSAeterna Zentaris upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Aeterna Zentaris to Buy with a $1.25 price target following the successful meeting with the FDA for a new Phase 3 trial of Macrilen and a separate, thorough QT study to address issues raised by the Complete Response Letter in November 2014.
April 13, 2015
10:15 EDTSQNMHigh option volume stocks
Subscribe for More Information
07:34 EDTAEZSAeterna Zentaris plans to conduct new Phase 3 clinical study of Macrilen
Aeterna Zentaris announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, or macimorelin, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency, as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization. This decision follows a positive and helpful meeting with the FDA regarding its New Drug Application for Macrilen. The Company's goal is to conduct a Phase 3 study that will satisfy the registration requirements of the European Medicines Agency as well as the FDA. The Company expects to receive comments from the EMA regarding the study design during a Scientific Advice Meeting in early May.
April 11, 2015
14:10 EDTHTWRLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
April 10, 2015
10:07 EDTIMGNHigh option volume stocks
Subscribe for More Information
08:37 EDTHTWRThoratec price target raised to $50 from $45 at Leerink
Subscribe for More Information
April 9, 2015
07:32 EDTHTWRHeartWare receives Health Canada approval for commercialization of assist system
HeartWare announced that it has received approval from Health Canada, the country's federal department responsible for helping Canadians maintain their health, to market the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.
April 7, 2015
10:48 EDTHTWRLeerink medical supplies & devices analyst has analyst/industry conference call
Subscribe for More Information
09:02 EDTAMEDAmedisys names Dan McCoy as COO, Martin Howard as CIO
Subscribe for More Information
April 6, 2015
17:19 EDTAMEDAmedisys Chief Medical Officer Fleming to depart
Subscribe for More Information
08:58 EDTHTWRCredit Suisse more optimistic on HeartWare
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use